Skip to main content
Top
Published in: The Journal of Headache and Pain 1/2018

Open Access 01-12-2018 | Research article

Dihydroergotamine inhibits the vasodepressor sensory CGRPergic outflow by prejunctional activation of α2-adrenoceptors and 5-HT1 receptors

Authors: Abimael González-Hernández, Jair Lozano-Cuenca, Bruno A. Marichal-Cancino, Antoinette MaassenVanDenBrink, Carlos M. Villalón

Published in: The Journal of Headache and Pain | Issue 1/2018

Login to get access

Abstract

Background

Dihydroergotamine (DHE) is an antimigraine drug that produces cranial vasoconstriction and inhibits trigeminal CGRP release; furthermore, it inhibits the vasodepressor sensory CGRPergic outflow, but the receptors involved remain unknown. Prejunctional activation of α2A/2C-adrenergic, serotonin 5-HT1B/1F, or dopamine D2-like receptors results in inhibition of this CGRPergic outflow. Since DHE displays affinity for these receptors, this study investigated the pharmacological profile of DHE-induced inhibition of the vasodepressor sensory CGRPergic outflow.

Methods

Pithed rats were pretreated i.v. with hexamethonium (2 mg/kg·min) followed by continuous infusions of methoxamine (20 μg/kg·min) and DHE (3.1 μg/kg·min). Then, stimulus-response curves (spinal electrical stimulation; T9-T12) or dose-response curves (i.v. injections of α-CGRP) resulted in frequency-dependent or dose-dependent decreases in diastolic blood pressure.

Results

DHE inhibited the vasodepressor responses to electrical stimulation (0.56–5.6 Hz), without affecting those to i.v. α-CGRP (0.1–1 μg/kg). This inhibition by DHE (not produced by the methoxamine infusions): (i) was abolished by pretreatment with the combination of the antagonists rauwolscine (α2-adrenoceptor; 310 μg/kg) plus GR127935 (5-HT1B/1D; 31 μg/kg); and (ii) remained unaffected after rauwolscine (310 μg/kg), GR127935 (31 μg/kg) or haloperidol (D2-like; 310 μg/kg) given alone, or after the combination of rauwolscine plus haloperidol or GR127935 plus haloperidol at the aforementioned doses.

Conclusion

DHE-induced inhibition of the vasodepressor sensory CGRPergic outflow is mainly mediated by prejunctional rauwolscine-sensitive α2-adrenoceptors and GR127935-sensitive 5-HT1B/1D receptors, which correlate with α2A/2C-adrenoceptors and 5-HT1B receptors, respectively. These findings suggest that DHE-induced inhibition of the perivascular sensory CGRPergic outflow may facilitate DHE’s vasoconstrictor properties resulting in an increased vascular resistance.
Appendix
Available only for authorised users
Literature
1.
go back to reference Dahlöf C, MaassenVanDenBrink A (2012) Dihydroergotamine, ergotamine, methysergide and sumatriptan–basic science in relation to migraine treatment. Headache 52:707–714CrossRefPubMed Dahlöf C, MaassenVanDenBrink A (2012) Dihydroergotamine, ergotamine, methysergide and sumatriptan–basic science in relation to migraine treatment. Headache 52:707–714CrossRefPubMed
2.
go back to reference Saper JR, Silberstein S (2006) Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache 46:S171–S181CrossRefPubMed Saper JR, Silberstein S (2006) Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache 46:S171–S181CrossRefPubMed
3.
go back to reference Silberstein SD, McCrory DC (2003) Ergotamine and dihydroergotamine: history, pharmacology and efficacy. Headache 43:144–166CrossRefPubMed Silberstein SD, McCrory DC (2003) Ergotamine and dihydroergotamine: history, pharmacology and efficacy. Headache 43:144–166CrossRefPubMed
4.
go back to reference Villalón CM, Centurión D, Willems EW, Arulmani U, Saxena PR, Valdivia LF (2004) 5-HT1B receptors and alpha2A/2C-adrenoceptors mediate external carotid vasoconstriction to dihydroergotamine. Eur J Pharmacol 484:287–290CrossRefPubMed Villalón CM, Centurión D, Willems EW, Arulmani U, Saxena PR, Valdivia LF (2004) 5-HT1B receptors and alpha2A/2C-adrenoceptors mediate external carotid vasoconstriction to dihydroergotamine. Eur J Pharmacol 484:287–290CrossRefPubMed
5.
go back to reference Buzzi MG, Carter WB, Shimizu T, Heath H III, Moskowitz MA (1991) Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagital sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 30:1193–1200CrossRefPubMed Buzzi MG, Carter WB, Shimizu T, Heath H III, Moskowitz MA (1991) Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagital sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 30:1193–1200CrossRefPubMed
6.
go back to reference Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48–56CrossRefPubMed Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48–56CrossRefPubMed
7.
go back to reference Marichal-Cancino BA, González-Hernández A, Manrique-Maldonado G, Ruiz-Salinas II, Altamirano-Espinoza AH, MaassenVanDenBrink A, Villalon CM (2012) Intrathecal dihydroergotamine inhibits capsaicin-induced vasodilatation in the canine external carotid circulation via GR127935-and rauwolscine-sensitive receptors. Eur J Pharmacol 692:69–77CrossRefPubMed Marichal-Cancino BA, González-Hernández A, Manrique-Maldonado G, Ruiz-Salinas II, Altamirano-Espinoza AH, MaassenVanDenBrink A, Villalon CM (2012) Intrathecal dihydroergotamine inhibits capsaicin-induced vasodilatation in the canine external carotid circulation via GR127935-and rauwolscine-sensitive receptors. Eur J Pharmacol 692:69–77CrossRefPubMed
8.
go back to reference Price TJ, Hargreaves KM, Cervero F (2006) Protein expression and mRNA cellular distribution of the NKCC1 cotransporter in the dorsal root and trigeminal ganglia of the rat. Brain Res 1112:146–158CrossRefPubMedPubMedCentral Price TJ, Hargreaves KM, Cervero F (2006) Protein expression and mRNA cellular distribution of the NKCC1 cotransporter in the dorsal root and trigeminal ganglia of the rat. Brain Res 1112:146–158CrossRefPubMedPubMedCentral
9.
go back to reference Rivera-Mancilla E, Avilés-Rosas VH, Manrique-Maldonado G, Altamirano-Espinoza AH, Villanueva-Castillo B, MaassenVanDenBrink A, Villalón CM (2017) The role of α1- and α2-adrenoceptor subtypes in the vasopressor responses induced by dihydroergotamine in ritanserin-pretreated pithed rats. J Headache Pain 18:104CrossRefPubMedPubMedCentral Rivera-Mancilla E, Avilés-Rosas VH, Manrique-Maldonado G, Altamirano-Espinoza AH, Villanueva-Castillo B, MaassenVanDenBrink A, Villalón CM (2017) The role of α1- and α2-adrenoceptor subtypes in the vasopressor responses induced by dihydroergotamine in ritanserin-pretreated pithed rats. J Headache Pain 18:104CrossRefPubMedPubMedCentral
10.
11.
go back to reference González-Hernández A, Marichal-Cancino BA, Lozano-Cuenca J, López-Canales JS, Muñoz-Islas E, Ramírez-Rosas MB, Villalón CM (2016) Heteroreceptors modulating CGRP release at neurovascular junction: potential therapeutic implications on some vascular related diseases. Biomed Res Int 2016:2056786CrossRefPubMedPubMedCentral González-Hernández A, Marichal-Cancino BA, Lozano-Cuenca J, López-Canales JS, Muñoz-Islas E, Ramírez-Rosas MB, Villalón CM (2016) Heteroreceptors modulating CGRP release at neurovascular junction: potential therapeutic implications on some vascular related diseases. Biomed Res Int 2016:2056786CrossRefPubMedPubMedCentral
12.
go back to reference Taguchi T, Kawasaki H, Imamura T, Takasaki K (1992) Endogenous calcitonin gene-related peptide mediates nonadrenergic noncholinergic depressor response to spinal cord stimulation in the pithed rats. Circ Res 71:357–364CrossRefPubMed Taguchi T, Kawasaki H, Imamura T, Takasaki K (1992) Endogenous calcitonin gene-related peptide mediates nonadrenergic noncholinergic depressor response to spinal cord stimulation in the pithed rats. Circ Res 71:357–364CrossRefPubMed
13.
go back to reference Smillie SJ, Brain SD (2011) Calcitonin gene-related peptide (CGRP) and its role in hypertension. Neuropeptides 45:93–104CrossRefPubMed Smillie SJ, Brain SD (2011) Calcitonin gene-related peptide (CGRP) and its role in hypertension. Neuropeptides 45:93–104CrossRefPubMed
14.
go back to reference Smillie SJ, King R, Kodji X, Outzen E, Pozsgai G, Fernandes E, Marshall N, De Winter P, Heads RJ, Dessapt-Baradez C, Gnudi L (2014) An ongoing role of α-calcitonin gene–related peptide as part of a protective network against hypertension, vascular hypertrophy, and oxidative stress. Hypertension 63:1056–1062CrossRefPubMed Smillie SJ, King R, Kodji X, Outzen E, Pozsgai G, Fernandes E, Marshall N, De Winter P, Heads RJ, Dessapt-Baradez C, Gnudi L (2014) An ongoing role of α-calcitonin gene–related peptide as part of a protective network against hypertension, vascular hypertrophy, and oxidative stress. Hypertension 63:1056–1062CrossRefPubMed
15.
go back to reference González-Hernández A, Marichal-Cancino BA, MaassenVanDenBrink A, Villalón CM (2018) Side effects associated with current and prospective antimigraine pharmacotherapies. Exp Opin Drug Metab Toxicol 14:25–41CrossRef González-Hernández A, Marichal-Cancino BA, MaassenVanDenBrink A, Villalón CM (2018) Side effects associated with current and prospective antimigraine pharmacotherapies. Exp Opin Drug Metab Toxicol 14:25–41CrossRef
16.
go back to reference Lozano-Cuenca J, González-Hernández A, Muñoz-Islas E, Sánchez-López A, Centurión D, Cobos-Puc LE, Villalón CM (2009) Effect of some acute and prophylactic antimigraine drugs on the vasodepressor sensory CGRPergic outflow in pithed rats. Life Sci 84:125–131CrossRefPubMed Lozano-Cuenca J, González-Hernández A, Muñoz-Islas E, Sánchez-López A, Centurión D, Cobos-Puc LE, Villalón CM (2009) Effect of some acute and prophylactic antimigraine drugs on the vasodepressor sensory CGRPergic outflow in pithed rats. Life Sci 84:125–131CrossRefPubMed
17.
go back to reference Sanders-Bush E, Mayer SE (2006) 5-hydroxytryptamine (serotonin): receptor agonists and antagonists. In: Brunton LL, Lazo JS, Parker KL (eds) Goodman & Gilman’s the pharmacological basis of therapeutics, 11th edn. Mc Graw Hill, New York, pp 297–316 Sanders-Bush E, Mayer SE (2006) 5-hydroxytryptamine (serotonin): receptor agonists and antagonists. In: Brunton LL, Lazo JS, Parker KL (eds) Goodman & Gilman’s the pharmacological basis of therapeutics, 11th edn. Mc Graw Hill, New York, pp 297–316
18.
go back to reference Villalón CM, Albarrán-Juárez JA, Lozano-Cuenca J, Pertz HH, Görnemann T, Centurión D (2008) Pharmacological profile of the clonidine-induced inhibition of vasodepressor sensory outflow in pithed rats: correlation with α2A/2C-adrenoceptors. Br J Pharmacol 154:51–59 Villalón CM, Albarrán-Juárez JA, Lozano-Cuenca J, Pertz HH, Görnemann T, Centurión D (2008) Pharmacological profile of the clonidine-induced inhibition of vasodepressor sensory outflow in pithed rats: correlation with α2A/2C-adrenoceptors. Br J Pharmacol 154:51–59
19.
go back to reference González-Hernández A, Muñoz-Islas E, Lozano-Cuenca J, Ramírez-Rosas MB, Sánchez-López A, Centurión D, Ramírez-San Juan E, Villalón CM (2010) Activation of 5-HT1B receptors inhibits the vasodepressor sensory CGRPergic outflow in pithed rats. Eur J Pharmacol 637:131–137CrossRefPubMed González-Hernández A, Muñoz-Islas E, Lozano-Cuenca J, Ramírez-Rosas MB, Sánchez-López A, Centurión D, Ramírez-San Juan E, Villalón CM (2010) Activation of 5-HT1B receptors inhibits the vasodepressor sensory CGRPergic outflow in pithed rats. Eur J Pharmacol 637:131–137CrossRefPubMed
20.
go back to reference González-Hernández A, Manrique-Maldonado G, Lozano-Cuenca J, Muñoz-Islas E, Centurión D, MaassenVanDenBrink A, Villalón CM (2011) The 5-HT1 receptors inhibiting the rat vasodepressor sensory CGRPergic outflow: further involvement of 5-HT1F, but not 5-HT1A or 5-HT1D, subtypes. Eur J Pharmacol 659:233–243CrossRefPubMed González-Hernández A, Manrique-Maldonado G, Lozano-Cuenca J, Muñoz-Islas E, Centurión D, MaassenVanDenBrink A, Villalón CM (2011) The 5-HT1 receptors inhibiting the rat vasodepressor sensory CGRPergic outflow: further involvement of 5-HT1F, but not 5-HT1A or 5-HT1D, subtypes. Eur J Pharmacol 659:233–243CrossRefPubMed
21.
go back to reference Manrique-Maldonado G, González-Hernández A, Altamirano-Espinoza AH, Marichal-Cancino BA, Ruiz-Salinas I, Villalón CM (2014) The role of prejunctional D2-like receptors mediating quinpirole-induced inhibition of the vasodepressor sensory CGRPergic out-flow in pithed rats. Basic Clin Pharmacol Toxicol 114:174–180CrossRefPubMed Manrique-Maldonado G, González-Hernández A, Altamirano-Espinoza AH, Marichal-Cancino BA, Ruiz-Salinas I, Villalón CM (2014) The role of prejunctional D2-like receptors mediating quinpirole-induced inhibition of the vasodepressor sensory CGRPergic out-flow in pithed rats. Basic Clin Pharmacol Toxicol 114:174–180CrossRefPubMed
22.
go back to reference Gillespie JS, MacLaren A, Pollock D (1970) A method of stimulating different segments of the autonomic outflow from the spinal column to various organs in the pithed cat and rat. Br J Pharmacol 40:257–267CrossRefPubMedPubMedCentral Gillespie JS, MacLaren A, Pollock D (1970) A method of stimulating different segments of the autonomic outflow from the spinal column to various organs in the pithed cat and rat. Br J Pharmacol 40:257–267CrossRefPubMedPubMedCentral
23.
24.
go back to reference Avilés-Rosas VH, Rivera-Mancilla E, Marichal-Cancino BA, Manrique-Maldonado G, Altamirano-Espinoza AH, MaassenVanDenBrink A, Villalón CM (2017) Olcegepant blocks neurogenic and non-neurogenic CGRPergic vasodepressor responses and facilitates noradrenergic vasopressor responses in pithed rats. Br J Pharmacol 174:2001–2014CrossRefPubMed Avilés-Rosas VH, Rivera-Mancilla E, Marichal-Cancino BA, Manrique-Maldonado G, Altamirano-Espinoza AH, MaassenVanDenBrink A, Villalón CM (2017) Olcegepant blocks neurogenic and non-neurogenic CGRPergic vasodepressor responses and facilitates noradrenergic vasopressor responses in pithed rats. Br J Pharmacol 174:2001–2014CrossRefPubMed
25.
go back to reference Decker N, Ehrhardt JD, Leclerc G, Schwartz J (1984) Postjunctional α-adrenoceptors: α1 and α2 subtypes in rat vasculature in vitro and in vivo. Naunyn Schmiedeberg’s Arch Pharmacol 326:1–6 Decker N, Ehrhardt JD, Leclerc G, Schwartz J (1984) Postjunctional α-adrenoceptors: α1 and α2 subtypes in rat vasculature in vitro and in vivo. Naunyn Schmiedeberg’s Arch Pharmacol 326:1–6
26.
27.
go back to reference Tfelt-Hansen PC, Koehler PJ (2008) History of the use of ergotamine and dihydroergotamine in migraine from 1906 and orward. Cephalalgia 28:877–886CrossRefPubMed Tfelt-Hansen PC, Koehler PJ (2008) History of the use of ergotamine and dihydroergotamine in migraine from 1906 and orward. Cephalalgia 28:877–886CrossRefPubMed
28.
go back to reference Cobos-Puc LE, Villalón CM, Sánchez-López A, Ramírez-Rosas MB, Lozano-Cuenca J, Pertz HH, Gömermann T, Centurión D (2009) Pharmacological characterization of ergotamine-induced inhibition of the cardioaccelerator sympathetic outflow in pithed rats. Naunyn Schmiedeberg's Arch Pharmacol 379:137–148CrossRef Cobos-Puc LE, Villalón CM, Sánchez-López A, Ramírez-Rosas MB, Lozano-Cuenca J, Pertz HH, Gömermann T, Centurión D (2009) Pharmacological characterization of ergotamine-induced inhibition of the cardioaccelerator sympathetic outflow in pithed rats. Naunyn Schmiedeberg's Arch Pharmacol 379:137–148CrossRef
29.
go back to reference Sánchez-López A, Centurión D, Vázquez E, Arulmani U, Saxena PR, Villalón CM (2004) Further characterization of the 5-HT1 receptors mediating cardiac sympatho-inhibition in pithed rats: pharmacological correlation with the 5-HT1B and 5-HT1D subtypes. Naunyn Schmiedeberg's Arch Pharmacol 369:220–227CrossRef Sánchez-López A, Centurión D, Vázquez E, Arulmani U, Saxena PR, Villalón CM (2004) Further characterization of the 5-HT1 receptors mediating cardiac sympatho-inhibition in pithed rats: pharmacological correlation with the 5-HT1B and 5-HT1D subtypes. Naunyn Schmiedeberg's Arch Pharmacol 369:220–227CrossRef
30.
go back to reference Boehm S, Kubista H (2002) Fine tuning of sympathetic transmitter release via ionotropic and metabotropic presynaptic receptors. Pharmacol Rev 54:43–99CrossRefPubMed Boehm S, Kubista H (2002) Fine tuning of sympathetic transmitter release via ionotropic and metabotropic presynaptic receptors. Pharmacol Rev 54:43–99CrossRefPubMed
31.
go back to reference De Jong AP, Verhage M (2009) Presynaptic signal transduction pathways that modulate synaptic transmission. Curr Opin Neurobiol 19:245–253CrossRefPubMed De Jong AP, Verhage M (2009) Presynaptic signal transduction pathways that modulate synaptic transmission. Curr Opin Neurobiol 19:245–253CrossRefPubMed
32.
go back to reference Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Marrion NV, Peters JA, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA (2017) CGTP collaborators - the concise guide to PHARMACOLOGY 2017/18: G protein-coupled receptors. Br J Pharmacol 174(S1):S17–S129CrossRefPubMedPubMedCentral Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Marrion NV, Peters JA, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA (2017) CGTP collaborators - the concise guide to PHARMACOLOGY 2017/18: G protein-coupled receptors. Br J Pharmacol 174(S1):S17–S129CrossRefPubMedPubMedCentral
33.
go back to reference Leysen JE, Gommeren W, Heylen L, Luyten WH, Van de Weyer I, Vanhoenacker P, Schotte A, Van Gompel P, Wouters R, Lesage AS (1996) Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol 50:1567–1580PubMed Leysen JE, Gommeren W, Heylen L, Luyten WH, Van de Weyer I, Vanhoenacker P, Schotte A, Van Gompel P, Wouters R, Lesage AS (1996) Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol 50:1567–1580PubMed
34.
go back to reference Jasper JR, Lesnick JD, Chang LK, Yamanishi SS, Chang TK, Hsu SA, Daunt DA, Bonhaus DW, Eglen RM (1998) Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding. Biochem Pharmacol 55:1035–1043CrossRefPubMed Jasper JR, Lesnick JD, Chang LK, Yamanishi SS, Chang TK, Hsu SA, Daunt DA, Bonhaus DW, Eglen RM (1998) Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding. Biochem Pharmacol 55:1035–1043CrossRefPubMed
35.
go back to reference Uhlén S, Porter AC, Neubig RR (1994) The novel alpha-2 adrenergic radioligand [3H]-MK912 is α2C selective among human α2A, α2B and α2C adrenoceptors. J Pharmacol Exp Ther 271:1558–1565 Uhlén S, Porter AC, Neubig RR (1994) The novel alpha-2 adrenergic radioligand [3H]-MK912 is α2C selective among human α2A, α2B and α2C adrenoceptors. J Pharmacol Exp Ther 271:1558–1565
36.
go back to reference Pauwels PJ (1996) Pharmacological properties of a putative 5-HT1B/1D receptor antagonist GR127935. CNS Drug Rev 2:415–428CrossRef Pauwels PJ (1996) Pharmacological properties of a putative 5-HT1B/1D receptor antagonist GR127935. CNS Drug Rev 2:415–428CrossRef
37.
go back to reference Adham N, Kao HT, Schechter LE, Bard J, Olsen M, Urquhart D, Durkin M, Hartig PR, Weinshank RL, Branchek TA (1993) Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A 90:408–412CrossRefPubMedPubMedCentral Adham N, Kao HT, Schechter LE, Bard J, Olsen M, Urquhart D, Durkin M, Hartig PR, Weinshank RL, Branchek TA (1993) Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A 90:408–412CrossRefPubMedPubMedCentral
38.
go back to reference Beer MS, Heald MA, McAllister G, Stanton JA (1998) Pharmacological characterisation of a cloned dog 5-HT1B receptor cell line. Eur J Pharmacol 360:117–121CrossRefPubMed Beer MS, Heald MA, McAllister G, Stanton JA (1998) Pharmacological characterisation of a cloned dog 5-HT1B receptor cell line. Eur J Pharmacol 360:117–121CrossRefPubMed
39.
go back to reference Price GW, Burton MJ, Collin LJ, Duckworth M, Gaster L, Göthert M, Jones BJ, Roberts C, Watson JM, Middlemiss DN (1997) SB-216641 and BRL-15572-compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedeberg's Arch Pharmacol 356:312–320CrossRef Price GW, Burton MJ, Collin LJ, Duckworth M, Gaster L, Göthert M, Jones BJ, Roberts C, Watson JM, Middlemiss DN (1997) SB-216641 and BRL-15572-compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedeberg's Arch Pharmacol 356:312–320CrossRef
40.
go back to reference Arnt J, Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neurophsychopharmacol 18:63–101CrossRef Arnt J, Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neurophsychopharmacol 18:63–101CrossRef
41.
go back to reference Millan MJ, Brocco M, Rivet JM, Audinot V, Newman-Tancredi A, Maiofiss L, Queriaux S, Despaux N, Peglion JL, Dekeyne A (2000) S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at α1- and α2-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents. J Pharmacol Exp Ther 292:54–66 Millan MJ, Brocco M, Rivet JM, Audinot V, Newman-Tancredi A, Maiofiss L, Queriaux S, Despaux N, Peglion JL, Dekeyne A (2000) S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at α1- and α2-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents. J Pharmacol Exp Ther 292:54–66
Metadata
Title
Dihydroergotamine inhibits the vasodepressor sensory CGRPergic outflow by prejunctional activation of α2-adrenoceptors and 5-HT1 receptors
Authors
Abimael González-Hernández
Jair Lozano-Cuenca
Bruno A. Marichal-Cancino
Antoinette MaassenVanDenBrink
Carlos M. Villalón
Publication date
01-12-2018
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 1/2018
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1186/s10194-018-0869-8

Other articles of this Issue 1/2018

The Journal of Headache and Pain 1/2018 Go to the issue